You're reading the free version. Trader adds the live tape and alerts.
Start tracking
AVTX Sale Disclosure
Sullivan Christopher Ryan · SEC Form 4 · Filed Aug 19, 2026
Sale
Calculated transaction value
$622.32K
Sullivan Christopher Ryan Chief Financial Officer
AVTX
Avalo Therapeutics
AVTX
Transaction date
Aug 18, 2026
Public filing date
Aug 19, 2026
Filing lag
Filed 1 day later
AVTX daily price context
Close on/before transaction
$19.71
Aug 18, 2026
First close after public filing
$19.82
Aug 20, 2026
30-day return after filing
-16.4%
Through Sep 18, 2026
Source details
- Reported owner
- Not disclosed
- Source asset code
- Security
- Security
- Common Stock
- Quantity / price
- 31,031 shares @ $20.05
- SEC ownership
- Direct
- Transaction code
- S
- Form
- 4
- Filing identifier
- 0001810417-26-000019
Filing cohort
Transactions in this filing
Showing 9 of 9
Trades
9
Issuers
1
Estimated value
$2.16M
Buys / sales
0 / 3
| Issuer | Transaction | Traded | Value |
|---|---|---|---|
| Avalo Therapeutics, Inc. AVTX | Exercise | Aug 18, 2026 | $306.59K |
| Avalo Therapeutics, Inc. AVTX Current | Sale | Aug 18, 2026 | $622.32K |
| Avalo Therapeutics, Inc. AVTX | Exercise | Aug 18, 2026 | $0 |
| Avalo Therapeutics, Inc. AVTX | Sale | Aug 17, 2026 | $753.33K |
| Avalo Therapeutics, Inc. AVTX | Sale | Aug 17, 2026 | $74.76K |
| Avalo Therapeutics, Inc. AVTX | Exercise | Aug 17, 2026 | $0 |
| Avalo Therapeutics, Inc. AVTX | Exercise | Aug 17, 2026 | $0 |
| Avalo Therapeutics, Inc. AVTX | Exercise | Aug 17, 2026 | $374.9K |
| Avalo Therapeutics, Inc. AVTX | Exercise | Aug 17, 2026 | $28.41K |